Regentis Biomaterials Secures Exclusive Four-Year Distribution Deal for GelrinC in Israel

Regentis Biomaterials has signed a four-year exclusive distribution agreement with AMI Medical Technologies to commercialize its GelrinC knee cartilage implant in Israel, marking a key step in the company's global commercialization strategy.

Chicago Metrowire Staff
••Healthcare
Regentis Biomaterials Secures Exclusive Four-Year Distribution Deal for GelrinC in Israel

Regentis Biomaterials Ltd. (NYSE American: RGNT), a regenerative medicine company focused on tissue repair solutions, has entered into a four-year exclusive distribution agreement with AMI Medical Technologies Ltd. for the commercialization of GelrinC® in Israel. GelrinC is Regentis' proprietary implant for repairing damaged knee cartilage and has already received regulatory approval from Israel's Ministry of Health for the same indication approved in Europe and being pursued in the United States. The deal represents a significant milestone in Regentis' commercialization strategy, providing a pathway to revenue in a key market while the company continues to advance its pivotal Phase 3 clinical program in the U.S.

Under the agreement, AMI Medical Technologies will leverage its established relationships with orthopedic surgeons, hospitals, and clinics to support the commercial introduction of GelrinC. The agreement includes minimum purchase requirements, with Regentis expecting initial revenue contributions beginning in 2027. The companies will also collaborate to establish reimbursement coverage for GelrinC with Israel's leading health maintenance organizations and promote adoption among orthopedic surgeons treating patients with focal cartilage defects. Until reimbursement coverage is established, patients may be able to access the implant through private health insurance.

The agreement is important because it provides Regentis with a commercial partner in Israel, a market where GelrinC already has regulatory approval, and lays the groundwork for revenue generation. It also supports Regentis' broader commercialization efforts in Europe and Israel as the company continues to develop its U.S. clinical program. GelrinC is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process. It aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.

For investors, the exclusive distribution agreement offers a clear path to commercialization in Israel and potential revenue starting in 2027, which could serve as a catalyst for the stock. The partnership with AMI Medical Technologies, which has deep relationships with Israeli orthopedic surgeons and healthcare providers, is expected to facilitate market penetration and adoption. Moreover, the collaboration on reimbursement coverage with health maintenance organizations is critical for ensuring patient access and driving sales. As Regentis continues to advance its U.S. Phase 3 program, the Israeli agreement demonstrates progress in its global commercialization strategy and provides validation of GelrinC's potential.

To view the full press release, visit https://ibn.fm/t1dw4. The latest news and updates relating to RGNT are available in the company's newsroom at https//ibn.fm/RGNT. For more information about Regentis Biomaterials, visit Regentis Biomaterials (NYSE American: RGNT).

MissionIR, a specialized communications platform, assists IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and a full array of tailored corporate communications solutions. For more information, please visit www.MissionIR.com. Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer.

Blockchain Registration

QR Code for Blockchain Registration